Plasma level and prognostic significance of VEGF, bFGF and MMP-9 in patients with advanced non-small-cell lung cancer.
- Author:
Jun ZHAO
1
;
Xu-yi LIU
;
Qing-yun ZHANG
;
Wei JIANG
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; blood; secondary; Enzyme-Linked Immunosorbent Assay; Female; Fibroblast Growth Factor 2; blood; Humans; Lung Neoplasms; blood; pathology; Male; Matrix Metalloproteinase 9; blood; Middle Aged; Neoplasm Metastasis; Prognosis; Vascular Endothelial Growth Factor A; blood
- From: Chinese Journal of Oncology 2005;27(11):676-679
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo measure plasma levels of VEGF, bFGF and MMP-9 in advanced non-small-cell lung cancer (NSCLC) patients and evaluate their prognostic value.
METHODSThe plasma levels of VEGF, bFGF and MMP-9 in 46 cases with advanced NSCLC were measured by ELISA before chemotherapy and in 30 cases after chemotherapy.
RESULTSThe plasma levels of VEGF, bFGF and MMP-9 in patients before chemotherapy were significantly higher than those in healthy control persons (P < 0.05). The correlation between plasma levels of VEGF and bFGF was significant, Spearman's r = 0.329 (P = 0.027). No correlation was found among the levels of angiogenic factors studied above and the following clinical parameters such as age, sex, histological subtype, differentiation of tumor cells, TNM-stage and also blood leukocyte, hemoglobin and platelet counts. The plasma level of MMP-9 in patients with extensive metastasis (including bone metastasis) was significantly higher than that in patients with bone metastasis only (P = 0.013). Reduction of plasma bFGF level after chemotherapy was a unique independent good prognostic factor (RR = 11.737, P = 0.02).
CONCLUSIONThe measurement of plasma levels of such angiogenic factors as VEGF, bFGF and MMP-9 in advanced NSCLC is helpful for prediction of metastasis tendency and evaluation of prognosis.
